Evidence map›Paper›PMID 11213865›Full record

ArticleDiabetes care2001

Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.

D B Rolka, A Fagot-Campagna, K M Narayan

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetes care, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2014
    Article
  4. Article
  5. Use of antithrombotic agents among U.S. stroke survivors, 2000-2006.American journal of preventive medicine · 2010
    Article
  6. Review
  7. Article
  8. Prescription of Aspirin for adults with Diabetes.International journal of diabetes in developing countries · 2008
    Article
  9. Article
  10. An appraisal of aspirin therapy in diabetes.Current diabetes reports · 2006
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Management of Diabetes with Coronary Artery Disease.Current treatment options in cardiovascular medicine · 2003
    Article
  17. Article
  18. The effect of salicylates on insulin sensitivity.The Journal of clinical investigation · 2001
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

D B RolkaDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. drolka@cdc.gov
A Fagot-Campagna
K M Narayan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSince 1997, the American Diabetes Association has recommended that aspirin therapy be considered for adults with diabetes who have cardiovascular disease (CVD) or CVD risk factors. We examined the prevalence of regular aspirin use among adults in the U.S. with diagnosed diabetes. RESEARCH DESIGN AND

methodsThe Third National Health and Nutrition Examination Survey (1988-1994) used a probability sample of the U.S. population and included an interview, physical examination, and laboratory studies. Among the survey participants were 1,503 adults (age > or =21 years) with self-reported diabetes. We defined regular aspirin use as reported having taken aspirin > or = 15 times in the previous month. CVD conditions were self-reported heart attack and stroke and symptoms of angina and claudication. CVD risk factors included smoking, hypertension, obesity, albuminuria, lipid abnormalities, and family history of heart attack.

resultsAn estimated 27% of adults with diabetes had CVD, and an additional 71% had one or more CVD risk factors. Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4.3); for non-Hispanic whites than for blacks, Mexican-Americans, and others (OR = 2.5); and for individuals age 40-59 years than for those <40 years (OR = 33.3).

conclusionsNearly every adult in the U.S. with diabetes has at least one risk factor for CVD and thus may be considered a potential candidate for aspirin therapy. During 1988-1994, only 20% (95% CI 16-23) took aspirin regularly Major efforts are needed to increase aspirin use.

Indexed as

Diabetes ComplicationsHealth SurveysAdultAlbuminuriaAngina PectorisAspirinCardiovascular DiseasesDiabetes MellitusDiabetic AngiopathiesHumansHyperlipidemiasHypertensionMiddle AgedMyocardial InfarctionObesityRisk FactorsAspirin

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.